checkAd

    INVESTOR ALERT  370  0 Kommentare Levi & Korsinsky, LLP Notifies Shareholders of Insmed Incorporated of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 13, 2016 -- INSM

    NEW YORK, NY--(Marketwired - July 26, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:

    To: All persons or entities who purchased or otherwise acquired securities of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM) between March 18, 2013 and June 8, 2016.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Apple Inc.!
    Short
    181,97€
    Basispreis
    0,94
    Ask
    × 14,97
    Hebel
    Long
    164,65€
    Basispreis
    0,94
    Ask
    × 14,97
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    You are hereby notified that a securities class action has commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired Insmed securities between March 18, 2013 and June 8, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/insmed-incorporated.

    The complaint alleges that, throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the data supporting Insmed's European marketing authorization application ("MAA") for lead product candidate ARIKAYCE was not likely to be approved by the European Medicines Agency ("EMA") for the treatment of NTM lung disease, and (2) therefore ARIKAYCE'S approval by the EMA and subsequent commercialization in Europe were less likely and/or imminent than Insmed led investors to believe.

    On June 8, 2016, Insmed announced it had withdrawn its MAA for ARIKAYCE from the EMA, revealing that the Committee for Medicinal Products for Human Use indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval.

    If you suffered a loss in Insmed you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/insmed-incorporated.

    Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

    CONTACT:
    Levi & Korsinsky, LLP
    Joseph E. Levi, Esq.
    30 Broad Street - 24th Floor
    New York, NY 10004
    Tel: (212) 363-7500
    Toll Free: (877) 363-5972
    Fax: (212) 363-7171
    www.zlk.com





    Verfasst von Marketwired
    INVESTOR ALERT Levi & Korsinsky, LLP Notifies Shareholders of Insmed Incorporated of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 13, 2016 -- INSM NEW YORK, NY--(Marketwired - July 26, 2016) - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: …

    Schreibe Deinen Kommentar

    Disclaimer